Low Growth Hormone Symptoms: When to See a Doctor

What Exactly Is Growth Hormone Deficiency?

Growth hormone deficiency occurs when the anterior pituitary gland produces insufficient somatotropin (GH), the 191-amino-acid peptide that signals the liver to produce insulin-like growth factor-1 (IGF-1). GHD can be congenital, acquired (from pituitary tumors, radiation, traumatic brain injury, or surgery), or idiopathic. In children, deficiency disrupts linear growth. In adults, the consequences shift toward body composition, bone density, metabolism, and cognitive function.

The Endocrine Society's 2011 clinical practice guideline, reaffirmed in subsequent updates, states that GHD "should be considered in patients with hypothalamic or pituitary disease, prior cranial irradiation, or childhood-onset GHD who have had retesting in adulthood." [1] That guidance covers acquired disease, but idiopathic adult-onset GHD is increasingly recognized as a distinct entity.

Pituitary Anatomy and Why It Fails

The anterior pituitary occupies a bony cavity called the sella turcica. A pituitary adenoma, even a microadenoma under 10 mm, compresses surrounding somatotroph cells and reduces GH secretion. Cranial radiation doses above 30 Gy damage the hypothalamus and blunt GH-releasing hormone (GHRH) output, with deficiency appearing as late as 10 years post-treatment. [2]

Childhood-Onset Versus Adult-Onset Disease

Children with GHD diagnosed before epiphyseal closure require retesting as adults. Data from the Hypopituitary Control and Complications Study (HypoCCS), which enrolled over 18,000 GHD patients across 20 countries, confirmed that roughly 25% of pediatric-onset patients show persistent deficiency at adult retesting. [3] Those who do not retest often accumulate years of untreated deficiency.

Specific Symptoms of Low Growth Hormone in Adults

Adults rarely complain about "not growing taller." Their symptoms are subtler. The most consistent findings across cohort studies are central adiposity, fatigue that does not resolve with rest, and a reduced sense of wellbeing.

Body Composition Changes

Visceral fat accumulates even when total caloric intake is unchanged. A landmark cross-sectional study of 333 GHD adults published in the Journal of Clinical Endocrinology and Metabolism found waist circumference 6.4 cm greater and lean body mass 5 kg lower in GHD subjects compared to age- and sex-matched controls. [4] Patients often describe this as "my body changed even though I didn't change my diet or exercise."

Fatigue and Sleep Disruption

GH is secreted in pulses during slow-wave sleep. Deficiency disrupts this axis bidirectionally: low GH impairs sleep architecture, and disrupted sleep further suppresses GH pulses. [5] Patients report fatigue that begins in the early afternoon, difficulty sustaining concentration, and non-restorative sleep despite adequate hours in bed.

Cognitive and Psychological Symptoms

Reduced GHD patients score lower on quality-of-life instruments. The Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) scale, validated across 8 European countries, shows mean scores 6 to 9 points worse in untreated GHD adults versus controls on a 25-point scale, with the steepest deficits in the energy and memory domains. [6]

Depression, reduced motivation, and social withdrawal can be early presentations. Because these overlap with primary depression and hypothyroidism, GHD is frequently misattributed.

Bone and Cardiovascular Findings

Untreated adult GHD reduces lumbar spine bone mineral density (BMD) by approximately 1 standard deviation below age-matched norms, raising 10-year fracture risk by a clinically meaningful margin. [7] Cardiovascular markers are also affected: increased low-density lipoprotein cholesterol, elevated C-reactive protein, and thickening of the carotid intima-media are documented in observational cohorts even after adjusting for BMI. [8]

Specific Symptoms of Low Growth Hormone in Children

Children present differently. The cardinal sign is slowed linear growth, but the complete picture includes several additional features that clinicians use to build their pre-test probability.

Height Velocity: The Most Specific Pediatric Marker

A height velocity below 4 cm per year in a child older than four years, or below 5 cm per year in a child between ages four and eight, is the threshold pediatric endocrinologists use to trigger GH testing. [9] This is more informative than absolute height, because a child who is short but growing at a normal velocity is unlikely to have GHD.

Bone age radiographs (left-hand X-ray compared to the Greulich-Pyle atlas) showing delay of two or more years relative to chronological age strengthen suspicion further.

Facial and Body Proportions

Children with GHD may have a rounded "cherubic" facial appearance, a relatively prominent forehead, and delayed dental eruption. Micropenis in male neonates (stretched penile length below 2.5 cm at term) is an important early sign of congenital hypopituitarism, because GH and gonadotropins often fail together in combined pituitary hormone deficiency. [10]

Delayed Puberty

GHD rarely acts in isolation. The same hypothalamic or pituitary pathology that suppresses GH secretion frequently blunts LH and FSH release, delaying breast development, testicular enlargement, and pubic hair onset beyond the normal age range.

Causes of Low Growth Hormone

Understanding the cause matters clinically because it predicts the likelihood of other pituitary hormone deficits and guides surveillance imaging.

Structural and Iatrogenic Causes

Pituitary adenomas (most commonly non-functioning macroadenomas and prolactinomas) cause GHD by direct compression or by treatment with surgery or radiation. Craniopharyngiomas, Rathke cleft cysts, and germinomas are the most frequent childhood structural causes. Post-traumatic hypopituitarism, now recognized in moderate-to-severe traumatic brain injury (TBI), affects an estimated 15 to 20% of TBI survivors when tested at one year post-injury. [11]

Idiopathic and Genetic Causes

Idiopathic GHD accounts for a large proportion of pediatric cases. Genetic mutations in GH1, GHRHR, POU1F1, PROP1, and LHX3 genes explain a minority of these cases. Whole-exome sequencing is now recommended for children with combined pituitary hormone deficiency by several pediatric endocrinology societies. [12]

Functional Suppression

Chronic psychosocial stress, severe caloric restriction, and uncontrolled type 1 diabetes can suppress GH axis output without structural pituitary pathology. This "functional GHD" resolves when the underlying condition is treated and does not carry the same long-term bone and cardiovascular risks as organic GHD.

How Is Low Growth Hormone Diagnosed?

A single random GH level is nearly useless. GH is secreted in brief pulses; between pulses, GH is undetectable in healthy adults. Diagnosis requires either a stimulation test or a combination of a low IGF-1 level with strong clinical probability.

The Gold-Standard: GH Stimulation Testing

Two stimulation tests are in clinical use in the United States. The insulin tolerance test (ITT) uses insulin-induced hypoglycemia to maximally stimulate GH secretion. A peak GH below 3 mcg/L confirms severe GHD in adults. [1] The ITT requires medical supervision and is contraindicated in patients with seizure disorders, ischemic heart disease, or age above 65. The glucagon stimulation test (GST) is safer and now preferred by many centers; the same peak GH cutoff of 3 mcg/L applies. [13]

In children, the standard cutoff has historically been 10 ng/mL, though many pediatric endocrinologists now apply a body-mass-index-adjusted cutoff because obesity blunts GH responses to stimulation independent of true GHD.

IGF-1 as a Screening Tool

A serum IGF-1 below the age- and sex-adjusted reference range, combined with two or more symptoms of GHD and a relevant structural or historical risk factor, gives sufficient pre-test probability to justify stimulation testing. An isolated low IGF-1 without symptoms or risk factors does not confirm GHD and may reflect nutritional status, liver disease, or hypothyroidism.

MRI of the Pituitary

All adults with confirmed GHD should receive gadolinium-enhanced MRI of the hypothalamic-pituitary region to identify structural pathology. Children with GHD confirmed on two stimulation tests should also undergo MRI before starting treatment, per the 2016 Pediatric Endocrine Society guidelines. [9]

When Should You See a Doctor? A Clinical Decision Framework

Most people with low energy or weight gain do not have GHD. The framework below is designed to help patients and clinicians identify which combination of findings justifies urgent versus routine evaluation.

Criteria for Urgent Evaluation (within one to two weeks)

Contact a physician promptly if any of the following apply:

• A child under age three whose linear growth has stopped for three or more months.
• An adult with a known pituitary tumor or prior pituitary surgery who develops new fatigue, weight gain, or cognitive decline.
• Neonatal hypoglycemia plus micropenis in a male infant, which signals combined pituitary hormone deficiency until proven otherwise.
• Any adult post-cranial radiation with new fatigue, reduced libido, and cold intolerance, because these together suggest panhypopituitarism.

These scenarios carry risk of adrenal insufficiency and central hypothyroidism alongside GHD. Missing those co-deficiencies is dangerous.

Criteria for Routine Evaluation (within two to four weeks)

Schedule a primary care or endocrinology appointment if you have two or more of the following, persisting for at least three months:

1. Increased abdominal fat despite stable diet and exercise habits.
2. Fatigue that is worse in the afternoon and not explained by thyroid or anemia testing.
3. Reduced lean muscle mass or declining exercise tolerance.
4. Non-restorative sleep without obstructive sleep apnea as an explanation.
5. Depressed mood, reduced motivation, or memory lapses not explained by primary psychiatric workup.
6. Bone density scan (DEXA) showing osteopenia below age 50 without another cause.

Bring any previous lab results, especially IGF-1, thyroid panel, CBC, and metabolic panel, to that appointment.

What to Expect at the Initial Visit

The physician will review your history for pituitary risk factors, order a fasting IGF-1 and IGF-binding protein 3 (IGFBP-3), and check competing diagnoses including hypothyroidism, hypogonadism, and anemia. If IGF-1 is low and the clinical picture is consistent, a GH stimulation test referral typically follows within two to four additional weeks.

Treatment Options for Low Growth Hormone

Treatment decisions depend on age, severity, confirmed etiology, and the presence of co-deficiencies.

Recombinant Human Growth Hormone (Somatropin)

Recombinant human GH (rhGH, somatropin) is FDA-approved for both pediatric and adult GHD. FDA-approved brand names include Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Eli Lilly), Saizen (EMD Serono), and Omnitrope (Sandoz). All are self-administered by subcutaneous injection, typically once daily at bedtime to mimic physiologic GH secretion. [14]

Adult dosing usually starts at 0.2 to 0.4 mg/day and is titrated every four to eight weeks based on IGF-1 levels, symptoms, and tolerability. Target IGF-1 is the mid-normal range for age and sex. Pediatric dosing is weight-based, commonly 0.025 to 0.035 mg/kg/day.

Monitoring on Therapy

After starting rhGH, the standard monitoring schedule is:

• IGF-1 at 4 to 6 weeks after each dose change.
• Fasting glucose and HbA1c at baseline and every 6 months, because rhGH causes mild insulin resistance.
• DEXA scan at baseline and every 12 to 24 months to track bone density recovery.
• Lipid panel at baseline and 6 months, because GHD-related dyslipidemia often improves with treatment. [15]

Efficacy Data from Clinical Trials

The KIMS (Kabi International Metabolic Surveillance) database, which tracked over 13,000 GHD adults receiving Genotropin across 31 countries, documented statistically significant reductions in waist circumference, improvements in lean body mass, and QoL-AGHDA score improvements averaging 4.2 points at 12 months of treatment. [3] Bone density in the lumbar spine increased by a mean of 2.8% per year in the first two years of therapy. [7]

A separate randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=166, 24-month follow-up) found that adults with severe adult-onset GHD who received somatropin 0.3 mg/day demonstrated a 0.63-SD improvement in lumbar spine Z-score versus placebo (P<0.001). [7]

Emerging Therapies: Long-Acting GH and Oral GHRH Agonists

Somapacitan (Sogroya, Novo Nordisk) received FDA approval in August 2021 for adult GHD. It is a long-acting GH derivative dosed once weekly, reducing injection burden from seven injections per week to one. The REAL 1 trial (N=301) showed non-inferiority to daily Norditropin on IGF-1 SDS at 34 weeks, with a comparable safety profile. [16] Lonapegsomatropin (TransCon hGH) is approved for pediatric GHD and achieves once-weekly dosing via a prodrug mechanism that releases native GH continuously.

Who Is at Highest Risk and Should Be Proactively Screened?

Several patient populations should have GH axis evaluation even before symptoms become obvious.

Survivors of childhood cancer who received cranial radiation above 18 Gy to the hypothalamic-pituitary region should have annual IGF-1 and clinical growth review from the end of treatment until final adult height, then transition to adult endocrinology for ongoing monitoring. The Children's Oncology Group Long-Term Follow-Up Guidelines specifically recommend this surveillance schedule. [2]

Adults who sustain moderate-to-severe TBI (Glasgow Coma Scale 3 to 12) should have pituitary function tested at three months and twelve months post-injury, as the Endocrine Society recommends, given the 15 to 20% rate of GHD in this population. [11]

Patients with any confirmed pituitary adenoma, regardless of whether it required surgery or radiation, warrant baseline pituitary hormone profiling including IGF-1 and GH stimulation testing if IGF-1 is low.

How Low Growth Hormone Differs from Other Fatigue-Causing Conditions

The symptom overlap between GHD, hypothyroidism, hypogonadism (low testosterone in men, estrogen deficiency in women), and adrenal insufficiency creates frequent diagnostic confusion.

A useful clinical distinction: GHD typically presents with central (visceral) fat accumulation and reduced lean mass together, which is less typical of isolated hypothyroidism. Hypothyroidism raises TSH and causes cold intolerance and constipation more consistently than GHD does. Low testosterone produces similar body composition changes to GHD but also reduces morning erections and libido in a pattern less prominent in isolated GHD. Adrenal insufficiency causes salt craving, postural hypotension, and hyperpigmentation (in primary disease) that GHD does not.

All four conditions can coexist, particularly in patients with pituitary or hypothalamic pathology. A complete anterior pituitary hormone panel, ordering TSH, free T4, morning cortisol, testosterone or estradiol alongside IGF-1, is the correct approach rather than testing one axis in isolation.

Practical Steps After Diagnosis

Once GHD is confirmed by stimulation testing, the sequence below reflects current Endocrine Society and Pediatric Endocrine Society guidance.

For adults, replace other pituitary hormones first. Adrenal insufficiency and hypothyroidism must be corrected before starting rhGH because GH affects cortisol metabolism and can unmask central adrenal insufficiency. Starting rhGH before replacing cortisol has caused adrenal crises. [1]

For children, GH therapy should start promptly once two stimulation tests confirm deficiency and MRI has been obtained, because earlier treatment preserves more growth potential. Each six-month delay in treatment during the prepubertal window costs approximately 1 to 2 cm of final adult height. [9]

Set realistic expectations with patients. Body composition and QoL improvements typically appear within three to six months. Full bone density recovery takes two to four years and may be incomplete in older adults who had a long period of untreated deficiency.